嗜酸性粒细胞增多综合征诊疗新进展

doi:10.35541/cjd.20230524

Abstract

Abstract: 【Abstract】 Hypereosinophilic syndrome (HES) represents a heterogeneous group of disorders. In 2012, the International Cooperative Working Group on Eosinophil Disorders, composed of multidisciplinary experts, updated the diagnostic criteria for HES, which have since been widely accepted. Over the past decade, based on new discoveries about disease pathogenesis, biomarkers, and therapeutic targets, further updates to the diagnosis and classification of HES have been proposed. This review summarizes the latest advances in the diagnostic criteria, classification, and treatment of HES, with the aim of standardizing the diagnosis, treatment, and management of HES and assisting clinicians in selecting effective therapeutic strategies in an accurate and timely manner.

Key words: Eosinophils, Hypereosinophilic syndrome, Diagnosis, Therapy, Classification

Li Xiaorong, Wang Wenjuan, Li Chengxin. Advances in the diagnosis and treatment of hypereosinophilic syndrome[J]. Chinese Journal of Dermatology,2026,e20230524. doi:10.35541/cjd.20230524

References ［34］

［1］	Hardy WR, Anderson RE. The hypereosinophilic syndromes［J］. Ann Intern Med, 1968,68（6）:1220⁃1229. DOI: 10.7326/0003⁃4819⁃68⁃6⁃1220.
［2］	Chusid MJ, Dale DC, West BC, et al. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature［J］. Medicine （Baltimore）, 1975,54（1）:1⁃27.
［3］	Simon HU, Rothenberg ME, Bochner BS, et al. Refining the definition of hypereosinophilic syndrome［J］. J Allergy Clin Immunol, 2010,126（1）:45⁃49. DOI: 10.1016/j.jaci.2010.03.042.
［4］	Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes［J］. J Allergy Clin Immunol, 2012,130（3）:607⁃612.e9. DOI: 10.1016/j.jaci.2012.02.019.
［5］	Shomali W, Gotlib J. World Health Organization⁃defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management［J］. Am J Hematol, 2022,97（1）:129⁃148. DOI: 10.1002/ajh.26352.
［6］	Valent P, Klion AD, Roufosse F, et al. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes［J］. Allergy, 2023,78（1）:47⁃59. DOI: 10.1111/all.15544.
［7］	Pineton de Chambrun G, Desreumaux P, Cortot A. Eosinophilic enteritis［J］. Dig Dis, 2015,33（2）:183⁃189. DOI: 10.1159/0003 69540.
［8］	Brambatti M, Matassini MV, Adler ED, et al. Eosinophilic myocarditis: characteristics, treatment, and outcomes［J］. J Am Coll Cardiol, 2017,70（19）:2363⁃2375. DOI: 10.1016/j.jacc. 2017.09.023.
［9］	Tennenbaum J, Groh M, Venditti L, et al. FIP1L1⁃PDGFRA⁃associated hypereosinophilic syndrome as a treatable cause of watershed infarction［J］. Stroke, 2021,52（10）:e605⁃e609. DOI: 10.1161/STROKEAHA.121.034191.
［10］	Valent P, Klion AD, Rosenwasser LJ, et al. ICON: eosinophil disorders［J］. World Allergy Organ J, 2012,5（12）:174⁃181. DOI: 10.1097/WOX.0b013e31827f4192.
［11］	Zayas J, Peters MS, Butterfield JH, et al. Clinical and histopathological features of hypereosinophilic syndrome with cutaneous involvement: the Mayo Clinic Experience［J］. J Cutan Pathol, 2023,50（5）:455⁃465. DOI: 10.1111/cup.14410.
［12］	Klion AD, Bochner BS, Gleich GJ, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report［J］. J Allergy Clin Immunol, 2006,117（6）:1292⁃1302. DOI: 10.1016/j.jaci.2006.02.042.
［13］	Akuthota P, Weller PF. Spectrum of eosinophilic end⁃organ manifestations［J］. Immunol Allergy Clin North Am, 2015,35（3）:403⁃411. DOI: 10.1016/j.iac.2015.04.002.
［14］	Curtis C, Ogbogu P. Hypereosinophilic syndrome［J］. Clin Rev Allergy Immunol, 2016,50（2）:240⁃251. DOI: 10.1007/s12016⁃015⁃8506⁃7.
［15］	Helbig G, Klion AD. Hypereosinophilic syndromes ⁃ an enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment［J］. Blood Rev, 2021,49:100809. DOI: 10.1016/j.blre.2021.100809.
［16］	Weller PF, Spencer LA. Functions of tissue⁃resident eosinophils［J］. Nat Rev Immunol, 2017,17（12）:746⁃760. DOI: 10.1038/nri. 2017.95.
［17］	Valent P, Gleich GJ, Reiter A, et al. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field［J］. Expert Rev Hematol, 2012,5（2）:157⁃176. DOI: 10.1586/ehm.11.81.
［18］	Klion AD, Ackerman SJ, Bochner BS. Contributions of eosinophils to human health and disease［J］. Annu Rev Pathol, 2020,15:179⁃209. DOI: 10.1146/annurev⁃pathmechdis⁃012419⁃032756.
［19］	Fulkerson PC, Rothenberg ME. Eosinophil development, disease involvement, and therapeutic suppression［J］. Adv Immunol, 2018,138:1⁃34. DOI: 10.1016/bs.ai.2018.03.001.
［20］	Moussiegt A, Müller R, Ebbo M, et al. IgG4⁃related disease and hypereosinophilic syndrome: overlapping phenotypes［J］. Autoimmun Rev, 2021,20（9）:102889. DOI: 10.1016/j.autrev.2021.102889.
［21］	Khoury P, Herold J, Alpaugh A, et al. Episodic angioedema with eosinophilia （Gleich syndrome） is a multilineage cell cycling disorder［J］. Haematologica, 2015,100（3）:300⁃307. DOI: 10. 3324/haematol.2013.091264.
［22］	Carpentier C, Schandené L, Dewispelaere L, et al. CD3（⁃）CD4（+） lymphocytic variant hypereosinophilic syndrome: diagnostic tools revisited［J］. J Allergy Clin Immunol Pract, 2021,9（6）:2426⁃2439.e7. DOI: 10.1016/j.jaip.2021.01.030.
［23］	Ledoult E, Groh M, Kahn JE, et al. Assessment of T⁃cell polarization on the basis of surface marker expression: Diagnosis and potential therapeutic implications in lymphocytic variant hypereosinophilic syndrome［J］. J Allergy Clin Immunol Pract, 2020,8（3）:1110⁃1114.e2. DOI: 10.1016/j.jaip.2019.08.049.
［24］	Carpentier C, Verbanck S, Schandené L, et al. Eosinophilia associated with CD3（⁃）CD4（+） T cells: characterization and outcome of a single⁃center cohort of 26 patients［J］. Front Immunol, 2020,11:1765. DOI: 10.3389/fimmu.2020.01765.
［25］	Shi Y, Wang C. What we have learned about lymphocytic variant hypereosinophilic syndrome: a systematic literature review［J］. Clin Immunol, 2022,237:108982. DOI: 10.1016/j.clim.2022. 108982.
［26］	Hwee J, Huynh L, Du S, et al. Hypereosinophilic syndrome in Europe: retrospective study of treatment patterns, clinical manifestations, and healthcare resource utilization［J］. Ann Allergy Asthma Immunol, 2023,130（6）:768⁃775. DOI: 10.1016/j.anai.2023.02.022.
［27］	Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1⁃PDGFRalpha⁃positive hypereosinophilic syndrome. Results of a multicenter prospective study［J］. Haematologica, 2007,92（9）:1173⁃1179. DOI: 10.3324/haematol.11420.
［28］	Groh M, Rohmer J, Etienne N, et al. French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes［J］. Orphanet J Rare Dis, 2023,18（1）:100. DOI: 10.1186/s13023⁃023⁃02696⁃4.
［29］	Klion A. Hypereosinophilic syndrome: approach to treatment in the era of precision medicine［J］. Hematology Am Soc Hematol Educ Program, 2018,2018（1）:326⁃331. DOI: 10.1182/asheducation⁃ 2018.1.326.
［30］	Panch SR, Bozik ME, Brown T, et al. Dexpramipexole as an oral steroid⁃sparing agent in hypereosinophilic syndromes［J］. Blood, 2018;132（5）:501⁃509. DOI: 10.1182/blood⁃2018⁃08⁃870204.
［31］	Menigoz C, Dirou S, Chambellan A, et al. Use of FeNO to predict anti⁃IL⁃5 and IL⁃5R biologics efficacy in a real⁃world cohort of adults with severe eosinophilic asthma［J］. J Asthma, 2023,60（6）:1162⁃1170. DOI: 10.1080/02770903.2022.2136526.
［32］	Khoury P, Abiodun AO, Holland⁃Thomas N, et al. Hypereosinophilic syndrome subtype predicts responsiveness to glucocorticoids［J］. J Allergy Clin Immunol Pract, 2018,6（1）:190⁃195. DOI: 10.1080/02770903.2022.2136526.
［33］	Verstovsek S, Tefferi A, Kantarjian H, et al. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia［J］. Clin Cancer Res, 2009,15（1）:368⁃373. DOI: 10. 1158/1078⁃0432.CCR⁃08⁃1302.
［34］	Iurlo A, Cattaneo D. Biologic therapies for hypereosinophilic disorders: from tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?［J］. Blood Rev, 2023,58:101014. DOI: 10.1016/j.blre.2022.101014.

[1]	Li Yanhong, Jiang Kun, Wu Zhuoxuan, Zhang Jianlan, Fang Meizhen, Liu Shuting, Wang Linlin, Hu Lei, Zhou Xiaoyong, Chen Liuqing, Chen Jinbo. Analysis of 18 cases of cutaneous adverse reactions associated with programmed death-1 inhibitors [J]. Chinese Journal of Dermatology, 2026, 59(8): 783-787.
[2]	Expert Group on the “Chinese expert consensus on sirolimus in the treatment of Kaposiform hemangioendothelioma （ edition）”. Chinese expert consensus on sirolimus in the treatment of Kaposiform hemangioendothelioma （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(8): 728-737.
[3]	Chinese Society of Dermatology, China Dermatologist Association. Chinese guideline for the diagnosis and treatment of cutaneous squamous cell carcinoma （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(8): 703-716.
[4]	Writing Committee Expert Group on “Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （ edition）”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(8): 717-727.
[5]	Wei Jin¹, Yan Huiwen¹, Zhang Jianzhong², Lun Wenhui¹. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis complicated by HIV infection: a clinical observation of 10 cases [J]. Chinese Journal of Dermatology, 2026, 59(7): 671-674.
[6]	Wang Linlin, Cao Lijuan, Chen Liuqing, Li Dongsheng, Hu Yanyan. Efficacy and safety of hemoporfin-mediated photodynamic therapy for port-wine stains on the extremities: a retrospective analysis [J]. Chinese Journal of Dermatology, 2026, 59(7): 637-644.
[7]	Zhang Guolong, Zhao Zijun. Aminolevulinic acid-based photodynamic therapy for cutaneous squamous cell carcinoma: current status, challenges, and perspectives [J]. Chinese Journal of Dermatology, 2026, 59(7): 626-631.
[8]	Hu Yu, Lu Yan, Chen Kun, Gu Heng. Standardization, precision, and full-cycle management: interpretation of Specifications for the Management of Vitiligo Patients Undergoing Home Phototherapy [J]. Chinese Journal of Dermatology, 2026, 59(7): 632-636.
[9]	Dermatology Professional Committee of Chinese Research Hospital Society, China Dermatologist Association. Guideline for the clinical application of narrowband ultraviolet B phototherapy in dermatology （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(7): 595-610.
[10]	Photodynamic Therapy Research Cooperative Group, Chinese Society of Dermatology, Chinese Association of Rehabilitation Dermatology & Photodynamic Therapy, Photomedicine Therapeutic Equipment Group, Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment. Guideline for the clinical application of aminolevulinic acid-based photodynamic therapy in the treatment of condyloma acuminatum （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(7): 611-618.
[11]	He Qing, Zhang Tao, Wang Xiuli, Gao Xinghua, Chen Hongduo, Liu Min, Qi Ruiqun. Biomarkers associated with malignant progression of actinic keratosis [J]. Chinese Journal of Dermatology, 2026, 59(7): 687-690.
[12]	Sun Songpeng, Long Junhong, Cao Bo, Xu Yue, Zhang Xiang′an, Cao Hui, Xie Jun, Gui Ping, Sun Xiaojun, Zhang Bo, Xu Zhijie, Li Jin′an, Wang Zhigang, Wu Wei, Yang Huiju, Wei Ping, Liu Congcong, Shen Qingbo, Yu Fan, Chu Hongchuan, Zhou Yangyang, Liu Jiaxin, Liu Yan, Huo Xingxiao, Chen Hang, Jing Tao, Gao Jing, Wang Yanxun, Wang Rui, Li Zhenyu, Zhang Shuxin. Efficacy and safety of Fuzhiqing ointment versus triamcinolone acetonide and econazole nitrate cream in the treatment of chronic perianal eczema: a multicenter, randomized, double-blind, controlled, equivalence trial [J]. Chinese Journal of Dermatology, 2026, 59(6): 564-570.
[13]	Tian Jing, Song Zhiqiang. Application of tape stripping to the detection of biomarkers in atopic dermatitis [J]. Chinese Journal of Dermatology, 2026, 59(6): 578-581.
[14]	Pediatric Dermatology Group, Chinese Society of Dermatology, Dermatology Group, Chinese Pediatric Society, Chinese Medical Association, Pediatric Group, Chinese Association of Rehabilitation Dermatology, Atopic Dermatitis Group, Chinese Association of Rehabilitation Dermatology, Pediatric Dermatology Group, China Dermatologist Association, Dermatology Group, the Society of Pediatrics, Chinese Medical Doctor Association. Chinese consensus on the prevention, treatment, and management of atopic dermatitis in children（2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(6): 487-504.
[15]	Du Xinran, Wang Xinhe, Li Siyu, Chen Moan, Yuan Shaojie, Yan Ran, Cheng Linyan, Guo Wanjun, Wang Yi, Li Fulun. Development and evaluation of a diagnostic scale for atopic dermatitis with the syndrome of wind dryness due to blood deficiency [J]. Chinese Journal of Dermatology, 2026, 59(6): 540-546.

Advances in the diagnosis and treatment of hypereosinophilic syndrome

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［34］

Related Articles 15

Metrics

Comments

Recommended 10